secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193125-26-088141
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome reports FY2025 net loss $212.4M; cash $653.5M; varegacestat NDA planned Q2 2026
--------------------------------------------------------------------------------

- Cash and equivalents $653.5M as of Dec 31, 2025; runway expected into 2028.
- Net loss of $212.4M for FY2025; R&D expenses $177.3M.
- Phase 3 RINGSIDE met primary endpoint: 84% reduction in risk of progression or death (HR=0.16, p<0.0001).
- NDA submission for varegacestat in desmoid tumors planned for Q2 2026.
- Three IND submissions for solid tumor ADCs (IM-1617, IM-1340, IM-1335) planned in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/0001193125-26-088141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-088141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer